Adjuvant therapy with imatinib mesylate after resection of primary high-risk gastrointestinal stromal tumors in Japanese patients

Tatsuo Kanda, Toshirou Nishida, Norihito Wada, Osamu Kobayashi, Masakazu Yamamoto, Akira Sawaki, Narikazu Boku, Masato Koseki, Toshihiko Doi, Yasushi Toh, Yoshihiro Kakeji, Toshiro Sugiyama, Yoshito Komatsu, Shojiro Kikuchi, Kyoji Ogoshi, Hitoshi Katai, Kazuhito Miyachi, Seiichi Hirota, Atsushi Ohtsu

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: Imatinib mesylate, a small-molecule tyrosine kinase inhibitor, is currently used for adjuvant therapy of patients who have undergone resection of high-risk gastrointestinal stromal tumors (GISTs). There are no data concerning the efficacy and safety of postoperative adjuvant therapy with imatinib for Japanese or East Asian patients with GIST. Methods: A single-arm, open-label, multicenter trial was conducted in 17 hospitals in Japan. The eligibility criteria included histologically proven primary high-risk GISTs with macroscopic complete resection. Patients were treated with imatinib at a dose of 400 mg/day for 1 year after surgery. The primary endpoint was recurrence-free survival as assessed by Kaplan-Meier analysis. The secondary endpoints were overall survival and safety. This study was registered with ClinicalTrials.gov, number NCT00171977. Results: A total of 64 patients were enrolled between September 2004 and July 2006. The median age of the patients was 59.5 years. Forty-nine (76.6%) patients completed the 1-year treatment, whereas 15 (23.4%) patients did not complete the treatment owing to recurrence, toxicities, and consent withdrawal. At the median follow-up period of 109 weeks, 20 patients had recurrence. The 3-year recurrence rate was 42.7% (95% confidence interval 29.2-56.3%), which exceeded the expected recurrence rate in this trial. The recurrence-free and overall survival rates at 2 years were 71.1 and 93.7%, respectively. The most frequent adverse drug reaction of any grade was eyelid edema (48.4%), followed by neutropenia (40.6%), leukopenia (39.1%), nausea (39.1%), rash (37.5%), and peripheral edema (37.5%), most of which were mild and manageable. Conclusions: Adjuvant therapy with imatinib at 400 mg/day for 1 year is well tolerated by Japanese patients and possibly reduces the risk of early recurrence of high-risk GISTs.

Original languageEnglish
Pages (from-to)38-45
Number of pages8
JournalInternational Journal of Clinical Oncology
Volume18
Issue number1
DOIs
Publication statusPublished - 2013 Feb

Fingerprint

Gastrointestinal Stromal Tumors
Recurrence
Therapeutics
Edema
Safety
Imatinib Mesylate
Survival
Leukopenia
Kaplan-Meier Estimate
Eyelids
Exanthema
Neutropenia
Drug-Related Side Effects and Adverse Reactions
Protein-Tyrosine Kinases
Nausea
Multicenter Studies
Japan
Survival Rate
Confidence Intervals

Keywords

  • Adjuvant therapy
  • Clinical trial
  • Gastrointestinal stromal tumor
  • GIST
  • Imatinib

ASJC Scopus subject areas

  • Oncology
  • Surgery
  • Hematology

Cite this

Adjuvant therapy with imatinib mesylate after resection of primary high-risk gastrointestinal stromal tumors in Japanese patients. / Kanda, Tatsuo; Nishida, Toshirou; Wada, Norihito; Kobayashi, Osamu; Yamamoto, Masakazu; Sawaki, Akira; Boku, Narikazu; Koseki, Masato; Doi, Toshihiko; Toh, Yasushi; Kakeji, Yoshihiro; Sugiyama, Toshiro; Komatsu, Yoshito; Kikuchi, Shojiro; Ogoshi, Kyoji; Katai, Hitoshi; Miyachi, Kazuhito; Hirota, Seiichi; Ohtsu, Atsushi.

In: International Journal of Clinical Oncology, Vol. 18, No. 1, 02.2013, p. 38-45.

Research output: Contribution to journalArticle

Kanda, T, Nishida, T, Wada, N, Kobayashi, O, Yamamoto, M, Sawaki, A, Boku, N, Koseki, M, Doi, T, Toh, Y, Kakeji, Y, Sugiyama, T, Komatsu, Y, Kikuchi, S, Ogoshi, K, Katai, H, Miyachi, K, Hirota, S & Ohtsu, A 2013, 'Adjuvant therapy with imatinib mesylate after resection of primary high-risk gastrointestinal stromal tumors in Japanese patients', International Journal of Clinical Oncology, vol. 18, no. 1, pp. 38-45. https://doi.org/10.1007/s10147-011-0339-7
Kanda, Tatsuo ; Nishida, Toshirou ; Wada, Norihito ; Kobayashi, Osamu ; Yamamoto, Masakazu ; Sawaki, Akira ; Boku, Narikazu ; Koseki, Masato ; Doi, Toshihiko ; Toh, Yasushi ; Kakeji, Yoshihiro ; Sugiyama, Toshiro ; Komatsu, Yoshito ; Kikuchi, Shojiro ; Ogoshi, Kyoji ; Katai, Hitoshi ; Miyachi, Kazuhito ; Hirota, Seiichi ; Ohtsu, Atsushi. / Adjuvant therapy with imatinib mesylate after resection of primary high-risk gastrointestinal stromal tumors in Japanese patients. In: International Journal of Clinical Oncology. 2013 ; Vol. 18, No. 1. pp. 38-45.
@article{5f1e13fa6781405083276741acf281b4,
title = "Adjuvant therapy with imatinib mesylate after resection of primary high-risk gastrointestinal stromal tumors in Japanese patients",
abstract = "Background: Imatinib mesylate, a small-molecule tyrosine kinase inhibitor, is currently used for adjuvant therapy of patients who have undergone resection of high-risk gastrointestinal stromal tumors (GISTs). There are no data concerning the efficacy and safety of postoperative adjuvant therapy with imatinib for Japanese or East Asian patients with GIST. Methods: A single-arm, open-label, multicenter trial was conducted in 17 hospitals in Japan. The eligibility criteria included histologically proven primary high-risk GISTs with macroscopic complete resection. Patients were treated with imatinib at a dose of 400 mg/day for 1 year after surgery. The primary endpoint was recurrence-free survival as assessed by Kaplan-Meier analysis. The secondary endpoints were overall survival and safety. This study was registered with ClinicalTrials.gov, number NCT00171977. Results: A total of 64 patients were enrolled between September 2004 and July 2006. The median age of the patients was 59.5 years. Forty-nine (76.6{\%}) patients completed the 1-year treatment, whereas 15 (23.4{\%}) patients did not complete the treatment owing to recurrence, toxicities, and consent withdrawal. At the median follow-up period of 109 weeks, 20 patients had recurrence. The 3-year recurrence rate was 42.7{\%} (95{\%} confidence interval 29.2-56.3{\%}), which exceeded the expected recurrence rate in this trial. The recurrence-free and overall survival rates at 2 years were 71.1 and 93.7{\%}, respectively. The most frequent adverse drug reaction of any grade was eyelid edema (48.4{\%}), followed by neutropenia (40.6{\%}), leukopenia (39.1{\%}), nausea (39.1{\%}), rash (37.5{\%}), and peripheral edema (37.5{\%}), most of which were mild and manageable. Conclusions: Adjuvant therapy with imatinib at 400 mg/day for 1 year is well tolerated by Japanese patients and possibly reduces the risk of early recurrence of high-risk GISTs.",
keywords = "Adjuvant therapy, Clinical trial, Gastrointestinal stromal tumor, GIST, Imatinib",
author = "Tatsuo Kanda and Toshirou Nishida and Norihito Wada and Osamu Kobayashi and Masakazu Yamamoto and Akira Sawaki and Narikazu Boku and Masato Koseki and Toshihiko Doi and Yasushi Toh and Yoshihiro Kakeji and Toshiro Sugiyama and Yoshito Komatsu and Shojiro Kikuchi and Kyoji Ogoshi and Hitoshi Katai and Kazuhito Miyachi and Seiichi Hirota and Atsushi Ohtsu",
year = "2013",
month = "2",
doi = "10.1007/s10147-011-0339-7",
language = "English",
volume = "18",
pages = "38--45",
journal = "International Journal of Clinical Oncology",
issn = "1341-9625",
publisher = "Springer Japan",
number = "1",

}

TY - JOUR

T1 - Adjuvant therapy with imatinib mesylate after resection of primary high-risk gastrointestinal stromal tumors in Japanese patients

AU - Kanda, Tatsuo

AU - Nishida, Toshirou

AU - Wada, Norihito

AU - Kobayashi, Osamu

AU - Yamamoto, Masakazu

AU - Sawaki, Akira

AU - Boku, Narikazu

AU - Koseki, Masato

AU - Doi, Toshihiko

AU - Toh, Yasushi

AU - Kakeji, Yoshihiro

AU - Sugiyama, Toshiro

AU - Komatsu, Yoshito

AU - Kikuchi, Shojiro

AU - Ogoshi, Kyoji

AU - Katai, Hitoshi

AU - Miyachi, Kazuhito

AU - Hirota, Seiichi

AU - Ohtsu, Atsushi

PY - 2013/2

Y1 - 2013/2

N2 - Background: Imatinib mesylate, a small-molecule tyrosine kinase inhibitor, is currently used for adjuvant therapy of patients who have undergone resection of high-risk gastrointestinal stromal tumors (GISTs). There are no data concerning the efficacy and safety of postoperative adjuvant therapy with imatinib for Japanese or East Asian patients with GIST. Methods: A single-arm, open-label, multicenter trial was conducted in 17 hospitals in Japan. The eligibility criteria included histologically proven primary high-risk GISTs with macroscopic complete resection. Patients were treated with imatinib at a dose of 400 mg/day for 1 year after surgery. The primary endpoint was recurrence-free survival as assessed by Kaplan-Meier analysis. The secondary endpoints were overall survival and safety. This study was registered with ClinicalTrials.gov, number NCT00171977. Results: A total of 64 patients were enrolled between September 2004 and July 2006. The median age of the patients was 59.5 years. Forty-nine (76.6%) patients completed the 1-year treatment, whereas 15 (23.4%) patients did not complete the treatment owing to recurrence, toxicities, and consent withdrawal. At the median follow-up period of 109 weeks, 20 patients had recurrence. The 3-year recurrence rate was 42.7% (95% confidence interval 29.2-56.3%), which exceeded the expected recurrence rate in this trial. The recurrence-free and overall survival rates at 2 years were 71.1 and 93.7%, respectively. The most frequent adverse drug reaction of any grade was eyelid edema (48.4%), followed by neutropenia (40.6%), leukopenia (39.1%), nausea (39.1%), rash (37.5%), and peripheral edema (37.5%), most of which were mild and manageable. Conclusions: Adjuvant therapy with imatinib at 400 mg/day for 1 year is well tolerated by Japanese patients and possibly reduces the risk of early recurrence of high-risk GISTs.

AB - Background: Imatinib mesylate, a small-molecule tyrosine kinase inhibitor, is currently used for adjuvant therapy of patients who have undergone resection of high-risk gastrointestinal stromal tumors (GISTs). There are no data concerning the efficacy and safety of postoperative adjuvant therapy with imatinib for Japanese or East Asian patients with GIST. Methods: A single-arm, open-label, multicenter trial was conducted in 17 hospitals in Japan. The eligibility criteria included histologically proven primary high-risk GISTs with macroscopic complete resection. Patients were treated with imatinib at a dose of 400 mg/day for 1 year after surgery. The primary endpoint was recurrence-free survival as assessed by Kaplan-Meier analysis. The secondary endpoints were overall survival and safety. This study was registered with ClinicalTrials.gov, number NCT00171977. Results: A total of 64 patients were enrolled between September 2004 and July 2006. The median age of the patients was 59.5 years. Forty-nine (76.6%) patients completed the 1-year treatment, whereas 15 (23.4%) patients did not complete the treatment owing to recurrence, toxicities, and consent withdrawal. At the median follow-up period of 109 weeks, 20 patients had recurrence. The 3-year recurrence rate was 42.7% (95% confidence interval 29.2-56.3%), which exceeded the expected recurrence rate in this trial. The recurrence-free and overall survival rates at 2 years were 71.1 and 93.7%, respectively. The most frequent adverse drug reaction of any grade was eyelid edema (48.4%), followed by neutropenia (40.6%), leukopenia (39.1%), nausea (39.1%), rash (37.5%), and peripheral edema (37.5%), most of which were mild and manageable. Conclusions: Adjuvant therapy with imatinib at 400 mg/day for 1 year is well tolerated by Japanese patients and possibly reduces the risk of early recurrence of high-risk GISTs.

KW - Adjuvant therapy

KW - Clinical trial

KW - Gastrointestinal stromal tumor

KW - GIST

KW - Imatinib

UR - http://www.scopus.com/inward/record.url?scp=84874051023&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874051023&partnerID=8YFLogxK

U2 - 10.1007/s10147-011-0339-7

DO - 10.1007/s10147-011-0339-7

M3 - Article

C2 - 22105894

AN - SCOPUS:84874051023

VL - 18

SP - 38

EP - 45

JO - International Journal of Clinical Oncology

JF - International Journal of Clinical Oncology

SN - 1341-9625

IS - 1

ER -